Bioxyne CEO and Managing Director Sam Watson talked with Proactive about the company’s major developments across medical psychedelics and cannabis in 2025, highlighting growing domestic and international momentum.
Watson described Bioxyne as a pharmaceutical manufacturer targeting patients with unmet clinical needs. Through its wholly owned subsidiary Breathe Life Sciences, the company produces treatments including medical cannabis, MDMA, and psilocybin for conditions such as PTSD, chronic pain, and depression.
He noted the growing demand and acceptance for these treatments, especially in Australia, where Bioxyne has delivered locally manufactured MDMA batches to a Victorian government hospital. “We were the first and one of the only companies licensed to manufacture those medicines,” he said, adding that products are being supplied across clinical trials, government-backed schemes and private clinics.
Watson also spoke about Bioxyne’s international expansion, including new operations in Costa Rica and Panama. He said there is strong recreational cannabis usage in the region, and the company aims to transition users into the legal medical framework. “The deal we’ve just done in Costa Rica is primarily for our pastilles — THC and CBD gummies,” he said.
In addition, Watson discussed the human impact of Bioxyne’s treatments, from helping PTSD sufferers restore daily function to improving quality of life for cancer patients undergoing chemotherapy. He also pointed to growth opportunities in the UK, Germany, and wider Europe, with financial results due in early 2026 expected to reflect the scale of expansion.
For more biotech updates and executive interviews, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe to the channel, and enable notifications for future content.
#Bioxyne #MedicalCannabis #MedicalMDMA #Psilocybin #PsychedelicMedicine #BreatheLifeSciences #PharmaceuticalManufacturing #BiotechStocks #MentalHealthTreatment
#AustraliaBiotech #PTSDTreatment #CannabisGummies #GlobalExpansion
Media coverage by Proactive – https://www.proactiveinvestors.com.au/companies/news/1084635/bioxyne-2025-manufacturing-psychedelics-for-ptsd.html